Case report: Drug rash with eosinophilia and systemic symptoms syndrome in a patient with anti–interferon-γ autoantibody–associated immunodeficiency

A 56-year-old Chinese woman with previous disseminated mycobacterium avium complex infection and recurrent cervical abscesses from Burkholderia cepacia complex visited our hospital. She was diagnosed with adult-onset immunodeficiency (AOID) and tested positive for interferon-γ–neutralizing autoantib...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 969912
Main Authors Nie, Yuxue, Wang, Han, Dong, Xiying, Pan, Siqi, Zhang, Ting, Ran, Jun, Zhang, Ying, Fan, Junping, Zhang, Linqi, Wang, Jinglan
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 22.08.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A 56-year-old Chinese woman with previous disseminated mycobacterium avium complex infection and recurrent cervical abscesses from Burkholderia cepacia complex visited our hospital. She was diagnosed with adult-onset immunodeficiency (AOID) and tested positive for interferon-γ–neutralizing autoantibody. Ceftazidime was administered as the initial antimicrobial treatment, which was later combined with sulfamethoxazole-trimethoprim (SMZ-TMP). She developed drug rash with eosinophilia and systemic symptoms (DRESS) syndrome after SMZ-TMP administration and improved after withdrawal of the culprit antibiotic and systemic glucocorticoids treatment. Her cervical infection was eventually cured after combined therapy of long-term antibiotics and anti–IFN-γ autoantibodies (AIGA) titer-lowering treatments including glucocorticoids, rituximab, and plasmapheresis. This is the first case of DRESS syndrome in the setting of AIGA-induced AOID and is worthy of notice.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Edited by: Chi Chiu Mok, Tuen Mun Hospital, Hong Kong SAR, China
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
Reviewed by: Hugo Chapdelaine, Montreal Clinical Research Institute (IRCM), Canada; David Andrew Fulcher, Australian National University, Australia
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.969912